A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today ...

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor’s antiplatelet effects in patients undergoing urgent surgery or experiencing major ...

Bentracimab rapidly reversed the antiplatelet effects of ticagrelor within 5 to 10 minutes. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...

The efficacy of P2Y12 monotherapy depends on the type of drug used after discontinuation of dual antiplatelet therapy (DAPT) for post-PCI patients, according to a new patient-level meta-analysis.

PARIS -- Antiplatelet de-escalation worked well following drug-coated balloon (DCB) placement for acute coronary syndrome (ACS), according to the first randomized trial on this subject. In ...

One year of dual antiplatelet therapy with one of two potent P2Y12 inhibitors-ticagrelor or prasugrel-in people with Type 1 or Type 2 diabetes who had received a drug-eluting stent did not offer the ...

ATLANTA -- In select patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes who were event-free for 1 month on dual antiplatelet therapy (DAPT), treatment with ...

Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome. HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting ...